ACE and dementia: The objective of this review is framed by the following PICO (Population, Intervention, Comparison, Outcome) question [10]: In adults or animal models at risk of or diagnosed with dementia or neuropsychiatric impairment (Population), does the use of RAAS-modulating agents such as ACE inhibitors or ARBs, or the measurement of RAAS activity (Intervention), compared to placebo, non-RAAS antihypertensive agents, or no treatment (Comparison), lead to improved cognitive function, delayed dementia progression, or reduced neuropsychiatric symptoms (Outcome)?